Relief Therapeutics

AdVita Lifescience is a company dedicated to improving the therapy and diagnosis of rare lung diseases. They develop diagnostic and pharmaceutical technologies aimed at enhancing treatment strategies for these conditions. The company's portfolio includes products focused on detecting patients with sarcoidosis and related diseases, as well as developing solutions for both human medicine and veterinary applications.

APR Applied Pharma Research s.a. is a pharmaceutical company based in Balerna, Switzerland, established in 1990. It specializes in the identification, development, manufacturing, and licensing of healthcare products across various therapeutic areas, including cancer supportive care, CNS disorders, dermatology, gynecology, and pain management. The company focuses on creating oral and topical formulations, offering a range of prescription and consumer healthcare products such as treatments for acute pain, cough, cold, and more. APR's innovative drug delivery systems and science-driven formulation technology enable it to address unmet medical needs, particularly in specialized therapeutic areas and rare diseases. With a strategic focus on markets in Europe and the United States, as well as rapidly growing regions like China, Russia, and Latin America, APR aims to improve the lives of patients and empower families through novel approaches to disease management.

FirstString Research, Inc. is a clinical-stage biopharmaceutical company based in Mount Pleasant, South Carolina, dedicated to discovering and developing therapies for inflammation-based medical conditions. Established in 2005, the company focuses on addressing unmet medical needs by mitigating excessive inflammation, calming inflamed tissues, and restoring the body’s natural healing processes. FirstString Research is advancing a pipeline of therapeutic products derived from its exclusive worldwide license of connexin-technology from the Medical University of South Carolina. This technology includes a portfolio of peptides that modulate junctional proteins essential for intercellular communication. The company is currently progressing its lead product, Granexin Gel, a topical formulation, through three Phase II clinical trials aimed at scar reduction and the treatment of chronic wounds.